Covered recipient · General Payments record
MICHAEL H SHANIK
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$184,107.88
441 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $138,422.50 | 65 |
| Consulting Fee | $15,849.50 | 5 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $11,812.50 | 5 |
| Food and Beverage | $9,345.94 | 270 |
| Travel and Lodging | $8,663.83 | 94 |
| Education | $13.61 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
Page 6 of 9; records 251–300 of 441 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MICHAEL H SHANIK
NPI 1386775740 · CMS profile ID 153116
Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
SMITHTOWN, NY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 6 of 9; records 251–300 of 441 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1386775740?year=2019&recipient=provider&page=6#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MICHAEL H SHANIK, NPI 1386775740, CMS profile ID 153116. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 9; records 251–300 of 441 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386775740?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). MICHAEL H SHANIK, NPI 1386775740, CMS profile ID 153116. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 9; records 251–300 of 441 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386775740?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- MICHAEL H SHANIK, NPI 1386775740, CMS profile ID 153116, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 9; records 251–300 of 441 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1386775740?year=2019&recipient=provider&page=6#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
441 matching records · $184,107.88 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 251–300 of 441.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc | $2,210.00 | 05/14/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703537631 | CMS |
| SANOFI-AVENTIS U.S. LLC | $21.44 | 05/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694306615 | CMS |
| Amgen Inc. | $149.05 | 05/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662764369 | CMS |
| Amgen Inc. | $65.81 | 05/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662764375 | CMS |
| Amgen Inc. | $194.86 | 05/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662764365 | CMS |
| Amgen Inc. | $152.89 | 05/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662764371 | CMS |
| Amgen Inc. | $163.02 | 05/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662764377 | CMS |
| Amgen Inc. | $356.88 | 05/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662764379 | CMS |
| Abbott Laboratories | $61.99 | 05/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 664407241 | CMS |
| Merck Sharp & Dohme Corporation | $12.29 | 05/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695554557 | CMS |
| Novo Nordisk Inc | $51.04 | 05/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703497367 | CMS |
| Novo Nordisk Inc | $125.00 | 05/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703524293 | CMS |
| Novo Nordisk Inc | $2,210.00 | 05/09/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703539987 | CMS |
| Amgen Inc. | $25.43 | 05/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662764345 | CMS |
| IBSA Pharma Inc. | $14.62 | 05/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 682236121 | CMS |
| Antares Pharma, Inc. | $21.52 | 05/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676453537 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $27.84 | 05/03/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700067789 | CMS |
| VIVUS, Inc. | $18.21 | 05/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694558371 | CMS |
| Novo Nordisk Inc | $51.04 | 05/01/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703497431 | CMS |
| Novo Nordisk Inc | $125.00 | 05/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703524567 | CMS |
| Novo Nordisk Inc | $2,210.00 | 05/01/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703540045 | CMS |
| Amarin Pharma Inc. | $24.09 | 04/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699135397 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,900.00 | 04/26/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700067811 | CMS |
| PFIZER INC. | $13.12 | 04/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672051375 | CMS |
| Aytu BioScience, Inc | $17.79 | 04/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 668011543 | CMS |
| Novo Nordisk Inc | $5.00 | 04/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703497117 | CMS |
| Novo Nordisk Inc | $42.92 | 04/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703497119 | CMS |
| Novo Nordisk Inc | $103.57 | 04/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703522761 | CMS |
| Novo Nordisk Inc | $2,210.00 | 04/25/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703539753 | CMS |
| Novo Nordisk Inc | $15.39 | 04/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 669551051 | CMS |
| Senseonics, Incorporated | $14.00 | 04/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 707956287 | CMS |
| SANOFI-AVENTIS U.S. LLC | $17.30 | 04/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694011633 | CMS |
| Becton, Dickinson and Company | $24.00 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703304481 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $122.43 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700067787 | CMS |
| Medtronic MiniMed, Inc. | $1,375.00 | 04/16/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648783581 | CMS |
| Amarin Pharma Inc. | $3,000.00 | 04/13/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699130115 | CMS |
| Shire North American Group Inc | $24.98 | 04/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 637916319 | CMS |
| Regeneron Healthcare Solutions, Inc. | $21.45 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673474521 | CMS |
| LifeScan, Inc. | $16.28 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671820917 | CMS |
| Amgen Inc. | $38.28 | 04/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662764472 | CMS |
| Companion Medical, Inc. | $17.00 | 04/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700795297 | CMS |
| Novo Nordisk Inc | $11.79 | 04/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 669551055 | CMS |
| Amgen Inc. | $2,400.00 | 04/07/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662764465 | CMS |
| Amgen Inc. | $400.00 | 04/07/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662764469 | CMS |
| Radius Health, Inc. | $18.75 | 04/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 683929537 | CMS |
| Abbott Laboratories | $122.74 | 04/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 664404785 | CMS |
| Amgen Inc. | $237.08 | 04/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662764457 | CMS |
| Aytu BioScience, Inc | $13.05 | 04/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 668011541 | CMS |
| Amgen Inc. | $16.92 | 04/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662764557 | CMS |
| Novo Nordisk Inc | $5,712.50 | 04/03/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750695481 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $136,686.79 | 36 |
| PY2024 | Principal investigator | $72,323.00 | 19 |
| PY2023 | Principal investigator | $31,534.77 | 27 |
| PY2022 | Principal investigator | $49,374.39 | 225 |
| PY2021 | Principal investigator | $58,482.27 | 456 |
| PY2020 | Principal investigator | $54,153.94 | 20 |
| PY2019 | Principal investigator | $64,830.84 | 22 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
36 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $5,520.00 | 12/31/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES OF LONG ISLAND PC | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism | No dispute reported | 06/30/2026 | 1202533851 |
| Principal investigator 1 | ABBVIE INC. | $556.47 | 12/11/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202530264 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,935.00 | 12/04/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES OF LONG ISLAND PC | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223289228 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $587.00 | 11/14/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES OF LONG ISLAND PC | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223288301 |
| Principal investigator 1 | ABBVIE INC. | $6,347.70 | 11/05/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202521505 |
| Principal investigator 1 | ABBVIE INC. | $3,505.95 | 10/09/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202513781 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,174.00 | 10/09/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES OF LONG ISLAND PC | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223286619 |
| Principal investigator 1 | ABBVIE INC. | $375.68 | 10/02/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202513039 |
| Principal investigator 1 | ABBVIE INC. | $3,001.62 | 09/18/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202511404 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,650.00 | 09/10/2025 | Non-covered Recipient Entity Endocrine Associates Of Long Island | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220817676 |
| Principal investigator 1 | ABBVIE INC. | $10,573.20 | 09/04/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202509166 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $587.00 | 09/04/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES OF LONG ISLAND PC | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223285101 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.88 | 09/01/2025 | Non-covered Recipient Entity Endocrine Associates Of Long Island | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220784409 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.30 | 08/26/2025 | Non-covered Recipient Entity Endocrine Associates Of Long Island | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220784411 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 08/26/2025 | Non-covered Recipient Entity Endocrine Associates Of Long Island | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220784413 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 08/26/2025 | Non-covered Recipient Entity Endocrine Associates Of Long Island | A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD | No dispute reported | 06/30/2026 | 1220784415 |
| Principal investigator 1 | ABBVIE INC. | $2,802.60 | 08/06/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202503307 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,174.00 | 07/31/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES OF LONG ISLAND PC | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223283286 |
| Principal investigator 1 | ABBVIE INC. | $3,171.15 | 07/02/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202494351 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,550.00 | 06/23/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES OF LONG ISLAND, PC | A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria | No dispute reported | 06/30/2026 | 1185549723 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $587.00 | 06/12/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES OF LONG ISLAND PC | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223281156 |
| Principal investigator 1 | ABBVIE INC. | $13,649.85 | 06/03/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202487985 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $587.00 | 05/15/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES OF LONG ISLAND PC | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223279810 |
| Principal investigator 1 | ABBVIE INC. | $5,593.05 | 05/07/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202484013 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,000.00 | 04/30/2025 | Non-covered Recipient Entity HIGHLAND MEDICAL HEMATOLOGY AND ONCOLOGY | A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria | No dispute reported | 06/30/2026 | 1185549721 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,174.00 | 04/22/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES OF LONG ISLAND PC | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223278536 |
| Principal investigator 1 | ABBVIE INC. | $5,686.20 | 04/03/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202473343 |
| Principal investigator 1 | ABBVIE INC. | $9,868.50 | 03/07/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202459720 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $587.00 | 03/06/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES OF LONG ISLAND PC | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223276073 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $1,000.00 | 03/05/2025 | Non-covered Recipient Entity Endocrine Associates of Long Island, PC | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | No dispute reported | 06/30/2026 | 1233994993 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $700.00 | 03/05/2025 | Non-covered Recipient Entity Endocrine Associates of Long Island, PC | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | No dispute reported | 06/30/2026 | 1233995021 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $587.00 | 02/13/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES OF LONG ISLAND PC | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223275231 |
| Principal investigator 1 | ABBVIE INC. | $8,904.60 | 02/06/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202448395 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,500.00 | 02/05/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES OF LONG ISLAND, PC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190305329 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $587.00 | 01/09/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES OF LONG ISLAND PC | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223273839 |
| Principal investigator 1 | ABBVIE INC. | $4,862.70 | 01/02/2025 | Non-covered Recipient Entity ENDOCRINE ASSOCIATES | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202434883 |